Sweileh Moutaz W
Faculty of Medicine and Allied Medical Sciences, An-Najah National University, Nablus, Palestine.
Department of Pathology, An-Najah National University Hospital, Nablus, Palestine.
Discov Oncol. 2025 Aug 3;16(1):1461. doi: 10.1007/s12672-025-03360-y.
Chimeric Antigen Receptor T cell (CAR-T) therapy is a groundbreaking, personalized immunotherapy that genetically engineers patient or donor-derived T cells to recognize and eliminate cancer cells. The U.S FDA has approved six CAR-T cell products in the past decade.
Given their clinical success and scientific novelty, this study aimed to map the research landscape surrounding the FDA-approved CAR-T cell therapies using bibliometric and knowledge mapping analysis.
A comprehensive title/abstract search was conducted in Scopus database for documents published between 2015 and 2024. The search terms included generic, trade, and abbreviated names of all FDA-approved CAR-T cell products. Bibliometric indicators including average annual growth rate, citation impact, key contributors, authorship pattern, and international collaboration were assessed. Visualization maps of co-authorship and keyword co-occurrence were generated using VOSviewer.
A total of 1163 documents were retrieved, with an average annual growth rate of 63.4%. Tisa-cel and axi-cel dominated the literature with 51.7% (n = 601) and 554 (47.6%) publications respectively. Ide-cel appeared in 152 (13.1%) publications, liso-cel in 125 (10.7%), and cilta-cel in 120 (10.3%). Brexu-cel was the least represented with 106 (9.1%) publications. The retrieved publications received 57,097 citations (mean = 49.1 citations per article; H-index = 103). Hematology and oncology-related journals were most prolific. The United States led global research output with 694 (59.7%) publications. Research output from European countries showed strong dependence on U.S.-based partnerships. Institutionally, the University of Texas MD Anderson Cancer Center, with 132 publications, was the leading institutions, followed by Moffitt Cancer Centre, and Memorial Sloan-Kettering Cancer Center. Authorship analysis revealed significant collaborative efforts, averaging 10.9 authors per article. Co-authorship map revealed academia-industry partnership. Temporal analysis of keywords revealed an evolution from CD19 target research (tisa-cel and axi-cel) to BCMA focused therapies (ide-cel and celta-cel). Thematic analysis showed four research themes: (1) molecular, therapeutic, and regulatory development of CAR-T constructs; (2) outcome of clinical trials; (3) economic and policy dimension of CAR-T therapy; and (4) treatment of relapsed and refractory multiple myeloma.
This study offers a translationally relevant perspective for clinicians, researchers, and policymakers, and underscores the evolving priorities in therapeutic development, access, and sustainability in precision oncology.
嵌合抗原受体T细胞（CAR-T）疗法是一种开创性的个性化免疫疗法，它通过基因工程改造患者或供体来源的T细胞，使其识别并消除癌细胞。在过去十年中，美国食品药品监督管理局（FDA）已批准了六种CAR-T细胞产品。
鉴于其临床成功和科学新颖性，本研究旨在使用文献计量学和知识图谱分析来描绘围绕FDA批准的CAR-T细胞疗法的研究概况。
在Scopus数据库中对2015年至2024年发表的文献进行全面的标题/摘要搜索。搜索词包括所有FDA批准的CAR-T细胞产品的通用名、商品名和缩写名。评估了文献计量指标，包括年均增长率、引用影响力、主要贡献者、作者模式和国际合作情况。使用VOSviewer生成合著者和关键词共现的可视化图谱。
共检索到1163篇文献，年均增长率为63.4%。替雷利珠单抗（Tisa-cel）和阿基仑赛（axi-cel）在文献中占主导地位，分别有51.7%（n = 601）和554篇（47.6%）出版物。伊德凯（Ide-cel）出现在152篇（13.1%）出版物中，利舒凯（liso-cel）出现在125篇（10.7%）中，西达基奥仑赛（cilta-cel）出现在120篇（10.3%）中。百悦泽（Brexu-cel）的出版物最少，有106篇（9.1%）。检索到的出版物共获得57097次引用（平均每篇文章49.1次引用；H指数 = 103）。血液学和肿瘤学相关期刊发表的文章最多。美国以694篇（59.7%）出版物引领全球研究产出。欧洲国家的研究产出显示出对美国合作关系的强烈依赖。在机构方面，德克萨斯大学MD安德森癌症中心以132篇出版物位居领先机构之首，其次是莫菲特癌症中心和纪念斯隆凯特琳癌症中心。作者分析显示出显著的合作努力，平均每篇文章有10.9位作者。合著者图谱显示了产学研合作关系。关键词的时间分析揭示了从CD19靶点研究（替雷利珠单抗和阿基仑赛）到以B细胞成熟抗原（BCMA）为重点的疗法（伊德凯和西达基奥仑赛）的演变。主题分析显示了四个研究主题：（1）CAR-T构建体的分子、治疗和监管发展；（2）临床试验结果；（3）CAR-T疗法的经济和政策层面；（4）复发难治性多发性骨髓瘤的治疗。
本研究为临床医生、研究人员和政策制定者提供了一个与转化相关的视角，并强调了精准肿瘤学中治疗开发、可及性和可持续性方面不断变化的优先事项。
